Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat
May 4, 2021 4:02 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.03), $0.79 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $99.4 million versus the consensus estimate of $77.04 million.
We continue to have strong Crysvita and Dojolvi launches and execute on our development priorities... More
